Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension
NCT ID: NCT00060918
Last Updated: 2015-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
1210 participants
INTERVENTIONAL
2001-06-30
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
NCT00123604
Comparison of Blood Pressure Medications on Metabolism
NCT00642434
Use of Beta-blockers and Risk of New Onset Diabetes
NCT01587638
Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure
NCT00497003
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension
NCT01970059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carvedilol
metoprolol
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have a history of mild to moderate hypertension (140-179 systolic; 90-1-9 diastolic).
* Must be on stable regimen of ACE (angiotensin converting enzyme) / ARB (angiotensin receptor blocker) treatment alone or in combination with other treatments.
* Patient''s laboratory result for HbA1c must be 6.5 - 8.5 (drug treated) or 6.5 - 7.5 (diet alone).
* Must be on a stable antidiabetic regimen (drug treated or diet alone).
Exclusion Criteria
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Glendale, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Burlingame, California, United States
GSK Investigational Site
Concord, California, United States
GSK Investigational Site
Encinitas, California, United States
GSK Investigational Site
Hemet, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Riverside, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Luis Obispo, California, United States
GSK Investigational Site
Spring Valley, California, United States
GSK Investigational Site
Aurora, Colorado, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Golden, Colorado, United States
GSK Investigational Site
Panama City, Florida, United States
GSK Investigational Site
St. Petersburg, Florida, United States
GSK Investigational Site
Honolulu, Hawaii, United States
GSK Investigational Site
Idaho Falls, Idaho, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
O'Fallon, Illinois, United States
GSK Investigational Site
Elkhart, Indiana, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Iowa City, Iowa, United States
GSK Investigational Site
Kalamazoo, Michigan, United States
GSK Investigational Site
Oak Park, Michigan, United States
GSK Investigational Site
Minneapolis, Minnesota, United States
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
Kansas City, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Bend, Oregon, United States
GSK Investigational Site
Oregon City, Oregon, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Georgetown, Texas, United States
GSK Investigational Site
Midland, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
The Colony, Texas, United States
GSK Investigational Site
Ogden, Utah, United States
GSK Investigational Site
Renton, Washington, United States
GSK Investigational Site
Madison, Wisconsin, United States
GSK Investigational Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
105517/346
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.